Co-Founder, Chief Executive Officer and Board Member
Sekar Kathiresan is co-founder and chief executive officer of Verve Therapeutics. He is also a member of the company’s board of directors. Dr. Kathiresan is a preventive cardiologist who has made groundbreaking discoveries of cardioprotective genetic mutations, which confer resistance to
President and Chief Operating Officer
Andrew Ashe is president and chief operating officer of Verve Therapeutics. Mr. Ashe is an accomplished biotech executive with over 20 years of experience in operations and legal management. Prior to joining Verve, he served as a senior executive and general counsel for several biotech companies,
Chief Scientific Officer
Andrew Bellinger is chief scientific officer of Verve Therapeutics. He is a general cardiologist at Brigham and Women’s Hospital and is board-certified in cardiovascular medicine and internal medicine. His scientific expertise includes biomedical engineering and drug delivery, computational
Vice President, Finance
Maggie Beaudoin is Vice President, Finance at Verve Therapeutics. She has 30 years of experience in finance, with 17 years in life sciences. Prior to joining Verve, she held corporate and clinical positions at Fisher Scientific, inVentiv Health and several biotech organizations.
Senior Vice President, Technical Operations
Jason Politi is the SVP, Technical Operations at Verve Therapeutics. Prior to joining Verve, Jason worked as SVP, Technical Operations at Prevail Therapeutics, where he helped to build and lead the CMC team as well as leading AAV gene therapy program management.
Senior Vice President, Human Resources and Facilities
Joan Nickerson is senior vice president, human resources and facilities at Verve Therapeutics with over 25 years’ experience in human resources. Prior to joining Verve, she led the HR functions at Dyax Corp., until it was acquired by Shire, and most recently at Sarepta Therapeutics. Ms.